Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)

NCT03635086 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chikungunya Virus Infection

Interventions

BIOLOGICAL: MV-CHIK lyophilised formulation, low dose
BIOLOGICAL: MV-CHIK liquid frozen formulation, low dose
BIOLOGICAL: MV-CHIK SPS® formulation, low dose
BIOLOGICAL: MV-CHIK liquid frozen formulation, high dose
OTHER: Placebo

Sponsor

Themis Bioscience GmbH